Literature DB >> 10334521

p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.

S Tortola1, E Marcuello, I González, G Reyes, R Arribas, G Aiza, F J Sancho, M A Peinado, G Capella.   

Abstract

PURPOSE: p53 gene and K-ras mutations are among the most common genetic alterations present in colorectal cancer. The prognostic utility of such mutations remains controversial. The purpose of this study was to prospectively evaluate the prognostic significance of p53 and K-ras gene mutations in colorectal cancer. PATIENTS AND METHODS: One hundred forty patients were analyzed. Tumors belonging to the microsatellite mutator phenotype were excluded (n = 8). Mutations at the K-ras and p53 genes were detected and characterized by restriction fragment length polymorphism, single-strand conformation polymorphism, and sequencing, as appropriate.
RESULTS: p53 mutations were detected in 66 (50%) and K-ras mutations were detected in 54 (41%) of the 132 patients. In 26 cases (20%), ras and p53 mutations coexisted; in 38 cases (29%), neither mutation was found. Multivariate analysis of the whole population analyzed (n = 132) showed that survival was strongly correlated with the presence of p53 mutations alone or in combination with K-ras mutations (P = .002; log-rank test). When only patients undergoing a radical resection were considered (R0; n = 101), p53 mutations were no longer of prognostic significance.
CONCLUSION: p53 mutations alone or in combination with K-ras mutations are correlated with a worse outcome. However, the routine use of these mutations as prognostic markers in the clinical setting is not recommended.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334521     DOI: 10.1200/JCO.1999.17.5.1375

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

1.  Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

Authors:  Wendy L Allen; Richard C Turkington; Leanne Stevenson; Gail Carson; Vicky M Coyle; Suzanne Hector; Philip Dunne; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Mol Cancer Ther       Date:  2012-06-04       Impact factor: 6.261

2.  Single nucleotide polymorphism seeking long term association with complex disease.

Authors:  Brian W Kirk; Matthew Feinsod; Reyna Favis; Richard M Kliman; Francis Barany
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

3.  Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer.

Authors:  Wesam A Nasif; Mahmoud Lotfy; Ibrahim H El-Sayed; Ayman El-Meghawry El-Kenawy; Mohamed El-Shahat; Nabil Gad El-Hak
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Impact of EGFR and p53 expressions on survival and quality of life in locally advanced oral squamous cell carcinoma patients treated with chemoradiation.

Authors:  Seema Gupta; Huma Khan; Vandana Singh Kushwaha; Nuzhat Husain; Mps Negi; Ashim Ghatak; Mlb Bhatt
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy.

Authors:  Neelesh Sharma; Maher Saifo; Ila R Tamaskar; Ramkumar Bhuvaneswari; Terry Mashtare; Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2010-12

Review 6.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

7.  Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?

Authors:  Nazım Emrah Koçer; Fazilet Kayaselçuk
Journal:  Target Oncol       Date:  2013-04-16       Impact factor: 4.493

Review 8.  Physical activity before and after diagnosis of colorectal cancer: disease risk, clinical outcomes, response pathways and biomarkers.

Authors:  David J Harriss; N Tim Cable; Keith George; Thomas Reilly; Andrew G Renehan; Najib Haboubi
Journal:  Sports Med       Date:  2007       Impact factor: 11.136

9.  Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer.

Authors:  Zuo Yunxia; Cao Jun; Zhu Guanshan; Lu Yachao; Zhou Xueke; Li Jin
Journal:  BMC Med Genet       Date:  2010-02-26       Impact factor: 2.103

10.  Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area.

Authors:  A Syed Sameer; Shakeel ul Rehman; Arshad A Pandith; Nidda Syeed; Zaffar A Shah; Nissar A Chowdhri; Khursheed A Wani; Mushtaq A Siddiqi
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.